Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial von Ferreri, Andrés J. M., Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P., Schorb, Elisabeth, Celico, Claudia, Falautano, Monica, Nonis, Alessandro, La Rosée, Paul, Binder, Mascia, Fabbri, Alberto, Ilariucci, Fiorella, Krampera, Mauro, Roth, Alexander, Hemmaway, Claire, Johnson, Peter W., Linton, Kim M., Pukrop, Tobias, Gørløv, Jettes Sønderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jense, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Zanni, Manuela, Krause, Stefan W., Schmoll, Hans J., Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Thurner, Lorenz, Cabras, Giuseppina, Pennese, Elsa, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Jurgen, Ferranti, Antonella, Cozens, Kelly, Burger, Elvira, Ielmini, Nicoletta, Cavalli, Franco, Zucca, Emanuele, Illerhaus, Gerald

Volltext